Format

Send to

Choose Destination
Eur J Pharmacol. 2013 Sep 15;716(1-3):17-23. doi: 10.1016/j.ejphar.2013.01.070. Epub 2013 Mar 13.

GABA(A) receptor modulation: potential to deliver novel pain medicines?

Author information

1
Neuroscience Drug Discovery, H. Lundbeck A/S, Ottiliavej 9, Valby DK-2500, Denmark and Aniona, Pederstrupvej 93, Ballerup, DK-2750, Denmark. Electronic address: gmun@lundbeck.com.

Abstract

GAB(A) (γ-aminobutyric acid) is abundantly expressed within the brain, and spinal cord pain circuits where it acts as the principal mediator of fast inhibitory neurotransmission. However, drugs that target GABA(A) receptor function such as the classical benzodiazepines have not been optimised to promote analgesia, are limited by side effects and are not routinely used for this purpose in humans. Compounds such as NS11394, L-838,417, HZ166 and TPA023 all bind to the same benzodiazepine site on the GABA(A) receptor to allosterically modulate receptor function and enhance the actions of GABA. By virtue of their ability to activate selected subtypes of GABA(A) receptors (principally those containing α2, α3 and α5 subunits) these compounds have been shown to possess excellent tolerability profiles in animals. Importantly, a number of these molecules also mediate profound analgesia in animal models of inflammatory and neuropathic pain. Other modulators such as neurosteroids bind to distinct sites on GABA(A) receptor α subunits, possess a unique pharmacology and are capable of targeting alternative GABA(A) receptor expressing populations. Moreover, neurosteroids also have pronounced analgesic actions in animal pain models. The continuing call for novel mechanism of action analgesics to target specific pathologies, especially in clinical neuropathic conditions, emphasizes the need to test modulators of GABA(A) receptor function in both human experimental pain models and pain patients.

KEYWORDS:

Allodynia; Benzodiazepine; Disinhibition; Hyperalgesia; Neuropathic; Neurosteroid

PMID:
23500203
DOI:
10.1016/j.ejphar.2013.01.070
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center